Hagens Berman has opened an investigation into The Cooper Companies over whether the medical-device maker was sufficiently transparent about sales practices affecting CooperVision, its largest reporting segment, and whether earlier disclosures violated securities laws. CooperVision represented roughly 67% of consolidated sales in fiscal 2025. During a June 4, 2026, earnings call, management reported 8% revenue growth, or 4% organically, and forecast full-year organic growth of 3.5% to 4.5%, citing solid demand outside Asia-Pacific for premium products. After Cooper reported third-quarter results on Sept. 9, management disclosed double-digit declines in legacy hydrogel products, U.S. channel inventory reductions and a CooperVision revenue outlook of $692 million to $706 million, representing an organic decline of 2% to flat growth. CEO Albert White III said the entire reduction in the segment’s guidance was tied to channel destocking. Cooper shares fell $9.31, or 14.6%, and closed at a 52-week low of $54.17, eliminating more than $1.7 billion in market value. Hagens Berman is seeking investors with substantial losses and people with non-public information, while noting that eligible SEC whistleblowers may receive up to 30% of a successful recovery.